1. Opioid use in Medicare Part D continued to decline in 2019, but vigilance is needed as COVID-19 raises new concerns Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, August 2020 Subject(s): COVID-19 -- economicsFraud -- prevention & controlGovernment RegulationMedicare Part D -- organization & administrationOpioid-Related Disorders -- economicsUnited StatesUnited States. Department of Health and Human Services
2. FDA’s risk evaluation and mitigation strategies: uncertain effectiveness in addressing the opioid crisis Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2020 Subject(s): Government RegulationOpioid-Related Disorders -- economicsRisk Evaluation and Mitigation -- legislation & jurisprudenceUnited StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug Administration
3. CMS should pursue strategies to increase the number of at-risk beneficiaries acquiring naloxone through Medicaid Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2020 Subject(s): Government RegulationMedicaid -- economicsNaloxone -- supply & distributionOpioid-Related Disorders -- economicsUnited StatesUnited States. Department of Health and Human Services
